Mohamed A Gouda (Mohamed Gouda, Mohammed Gouda)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 18

Top Topics

Advanced Non Small Cell Lung Cancer

Top Venues

NPJ precision oncology

JCO precision oncology

CA: a cancer journal for clinicians

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians 74 (5) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Vivek Subbiah, Mohamed A Gouda, J Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria E Cabanillas, Mimi Hu, Luz E Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer. NPJ precision oncology 8 (1) (2024)
Kalevi Kairemo, Homer A Macapinlac, Mohamed A Gouda, Vivek Subbiah
Assessing the Effectiveness of Selective RET Inhibitors in RET-Positive Cancers through Fluorodeoxyglucose Uptake Analysis. Diagnostics (Basel, Switzerland) 14 (17) (2024)
Mohamed A Gouda, Lars Buschhorn, Andreas Schneeweiß, Adam Wahida, Vivek Subbiah
N-of-1 Trials in Cancer Drug Development. Cancer discovery (2023)
Ryan A Denu, Justin Tyler Moyers, Mohamed A Gouda, Anthony P Conley, Alexander J F Lazar, Vivek Subbiah
The landscape of alterations from 1407 ultra-rare sarcomas from the AACR GENIE database: Clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Aditya V Shreenivas, Filip Janku, Mohamed A Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
ALK fusions in the pan-cancer setting: another tumor-agnostic target? NPJ precision oncology 7 (1) (2023)
Mohamed A Gouda, Blessie Elizabeth Nelson, Lars Buschhorn, Adam Wahida, Vivek Subbiah
Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Blessie Elizabeth Nelson, Neha K Reddy, Jason T Huse, Behrang Amini, Mirella Nardo, Mohamed A Gouda, Shiao-Pei Weathers, Vivek Subbiah
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ precision oncology 7 (1) (2023)
Mohamed A Gouda, Vivek Subbiah
Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 43 (2023)
Mohamed A Gouda, Dzifa Y Duose, Morten Lapin, Stephanie Zalles, Helen J Huang, Yuanxin Xi, Xiaofeng Zheng, Amira I Aldesoky, Alshimaa M Alhanafy, Mohamed A Shehata, Jing Wang, Edmund S Kopetz, Funda Meric-Bernstam, Ignacio I Wistuba, Rajyalakshmi Luthra, Filip Janku
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific Signatures. The oncologist (2022)
Morten Lapin, Helen J Huang, Sharmeen Chagani, Milind M Javle, Rachna T Shroff, Shubham Pant, Mohamed A Gouda, Anjali Raina, Kiran Madwani, Veronica R Holley, S Greg Call, Derek J Dustin, Richard B Lanman, Funda Meric-Bernstam, Victoria M Raymond, Lawrence N Kwong, Filip Janku
Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO precision oncology 6 (2022)
Mohamed A Gouda, Helen J Huang, Sarina A Piha-Paul, S Greg Call, Daniel D Karp, Siqing Fu, Aung Naing, Vivek Subbiah, Shubham Pant, Derek J Dustin, Apostolia-Maria Tsimberidou, David S Hong, Jordi Rodon Ahnert, Funda Meric-Bernstam, Filip Janku
Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO precision oncology 6 (2022)
Mohamed A Gouda, Emily Ong, Helen J Huang, Laron W McPhaul, Steve Yoon, Filip Janku, Andrew G Gianoukakis
Ultrasensitive detection of BRAF V600E mutations in circulating tumor DNA of patients with metastatic thyroid cancer. Endocrine 76 (2) (2022)